<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901458</url>
  </required_header>
  <id_info>
    <org_study_id>ITZ-003</org_study_id>
    <secondary_id>CIV-13-10-011663</secondary_id>
    <nct_id>NCT01901458</nct_id>
  </id_info>
  <brief_title>Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®</brief_title>
  <acronym>optiMaL</acronym>
  <official_title>Prospective Randomized Trial Comparing Efficiency of Peripheral Blood Progenitor Cell Collection in Allogeneic Donors Using the Spectra Optia® IDL Set in Comparison With the Spectra Optia® MNC Collection Set</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharma USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the advantage of the Spectra Optia® IDL set compared to the standard
      collection set for collection of peripheral blood progenitor cells using the Spectra Optia®
      apheresis system. The study will assess the reduction of apheresis time to obtain the
      required amount of hematopoietic progenitor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral blood progenitor cells (PBPC) collected by apheresis are the most common stem cell
      source for allogeneic hematopoietic stem cell transplantation.

      Recently, Terumo BCT introduced a novel automated apheresis system for PBPC collection. The
      Spectra Optia® apheresis system uses the Spectra Optia® Collection set and the MNC software
      for PBPC collection. This system combines continuous centrifugation (high g) and subsequent
      cellular collection into an elutriation chamber, where the platelets are elutriated from
      mononuclear cells. An optical sensor detects when red blood cells begin to be elutriated and
      subsequently triggers the collection of the buffy coat into the product bag by flushing the
      chamber with donor plasma. Thus PBPCs are harvested intermittently. In contrast, the same
      apheresis systems in combination with the Spectra Optia® IDL set and the WBC-D software,
      which has been designed to perform leukodepletion procedures, permits continuous PBPC
      centrifugation (low g) and harvesting.

      The investigators hypothesis is that the use of the IDL set with manual adaption of the
      WBC-D-software allows a more efficient PBPC collection compared to the collection set which
      is recommended for PBPC collection. The apheresis time to collect the same amount of target
      cells dependent on the donors peripheral blood count will be shortened. In addition, the
      investigators want to compare both systems with respect to the cellular composition of the
      apheresis product and the donors platelet loss and coagulation parameters during apheresis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Throughput (TP)</measure>
    <time_frame>Day 1</time_frame>
    <description>Efficiency of peripheral blood progenitor cell collection measured as throughput (collection rate (CR) per minute)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR per total blood volume (TBV)</measure>
    <time_frame>Day 1</time_frame>
    <description>Efficiency of peripheral blood progenitor cell collection measured as CR per TBV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection efficiency (CE) 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of harvested cells per processed cells (calculated by use of the peripheral blood progenitor cell counts pre and post apheresis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE2</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of harvested cells per processed cells (calculated by use of the peripheral blood progenitor cell count pre apheresis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product T cells</measure>
    <time_frame>Day 1</time_frame>
    <description>% T cells as a definition of the cellular composition of the product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product NK cells</measure>
    <time_frame>Day 1</time_frame>
    <description>% NK cells as a definition of the cellular composition of the product</description>
  </secondary_outcome>
  <other_outcome>
    <measure>levels of electrolytes before and after apheresis</measure>
    <time_frame>day 1, day 30</time_frame>
    <description>sodium, potassium and calcium are measured before and after apherese and 30 days after collection</description>
  </other_outcome>
  <other_outcome>
    <measure>kinetics of peripheral blood cell count</measure>
    <time_frame>day 1, day30</time_frame>
    <description>measurement of the peripheral blood cell count before and after apheresis and 30 days after collection</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral blood CD62P before and after apheresis</measure>
    <time_frame>day 1</time_frame>
    <description>Percentage of CD62P positive platelets as a measure of platelet activation during apheresis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Allogeneic Donors</condition>
  <condition>Granulocyte Colony-stimulating Factor (G-CSF) Mobilized</condition>
  <arm_group>
    <arm_group_label>IDL-Set</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MNC-Set</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectra Optia® IDL-Set</intervention_name>
    <description>Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator</description>
    <arm_group_label>IDL-Set</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectra Optia® Collection Set</intervention_name>
    <description>Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator</description>
    <arm_group_label>MNC-Set</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ability to give informed consent to participate in the study

          -  meets german eligibility criteria (ZKRD-Standards, hemotherapy guidelines) for
             peripheral blood stem cell donation

          -  has been treated with G-CSF 10 µg per kg per day for 5 days

        Exclusion Criteria:

          -  demand of concurrent plasma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes C Fischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich Heine University Hospital Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cellex GmbH / Zentrum für Zellgewinnung (Standort Köln)</name>
      <address>
        <city>Cologne</city>
        <zip>50670</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Transplantantionsdiagnostik und Zelltherapeutika</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apheresis</keyword>
  <keyword>peripheral blood progenitor cells</keyword>
  <keyword>peripheral blood stem cells</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

